新华制药(000756.SZ)：获得间苯三酚注射液药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the injection of phenobarbital, which is intended for the treatment of acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1] Company Summary - Xinhua Pharmaceutical has obtained the drug registration certificate for the injection of phenobarbital, indicating a significant regulatory milestone for the company [1]